New York State Contract Reporter #25019

NYS OASAS Solicitation for FDA-Approved Intranasal Naloxone and Online Portal

This procurement opportunity from the New York State Office of Addiction Services and Supports (NYS OASAS) seeks a supplier for FDA-approved intranasal naloxone and an associated online ordering portal. - Government Buyer: - New York State Office of Addiction Services and Supports (NYS OASAS), Contracts and Procurement Bureau - Office location: CMS 2, 1450 Western Avenue, 5th Floor, Albany, NY - OEMs and Vendors Mentioned: - Emergent Devices Inc. (noted as a past vendor for similar contracts) - Products/Services Requested: - FDA-approved intranasal naloxone, 4 mg per 0.1 mL solution - Supplied to NYS OASAS-Approved Providers - No specific part number provided - Online ordering and tracking portal for naloxone distribution - Quantities and Contract Value: - Purchases made on an as-needed basis; no guaranteed minimum quantity - Initial purchase authorization up to $8 million, with potential for increase - Unique or Notable Requirements: - Vendor must provide and maintain an online portal for ordering and tracking - Distribution is state-wide to approved providers - Only FDA-approved intranasal naloxone products are eligible - Period of Performance: - Five-year contract term, starting from award date - Place of Performance/Delivery: - State-wide across New York - Central office: CMS 2, 1450 Western Avenue, 5th Floor, Albany, NY

Description

The New York State Office of Addiction Services and Supports (NYS OASAS) is soliciting bids through IFB 25019 for FDA-approved intranasal naloxone, 4 mg per 0.1 mL solution. The procurement aims to award a contract to provide naloxone to NYS OASAS-Approved Providers and related organizations via an online ordering and tracking portal maintained by the bidder. The contract term is five years, with purchases made on an as-needed basis and no guarantee of purchase volume. The initial purchase authorization is anticipated to be up to $8 million, with potential increases subject to approval.

View original listing